Phase I study of GC33 in patients with Advanced Hepatocellular Carcinoma (HCC)

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221218

Enrollment

Registered

2010-08-26

Start date

2010-08-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Interventions

investigational material(s) Generic name etc : GC33 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -ECOG Performance Status of 0-1 -Histologically confirmed hepatocellular carcinoma(without fibrolamellar subtype) -Child-Pugh A or B

Exclusion criteria

Exclusion criteria: -Child-Pugh -Patients with significant central nervous system disorder caused by hepatic encephalopathy -Patients with uncontrolable ascites

Design outcomes

Primary

Measure	Time frame
Safety, Tolerability CTCAE ver4.0	—

Secondary

Measure	Time frame
Pharmacokinetics,biomarker, efficacy RECIST ver1.1	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026